Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory Cancers

Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory Cancers

To study the frequency with which targeted tumor sequencing results will lead to implemented change in care, this study assessed tumors from 100 patients for utility, feasibility, and limitations of genomic sequencing for genomically guided therapy or other clinical purpose in the setting of a multi...

Full description

Bibliographic Details
Main Authors: Hirshfield, Kim M., Tolkunov, Denis, Zhong, Hua, Ali, Siraj M., Stein, Mark N., Murphy, Susan, Vig, Hetal, Vazquez, Alexei, Glod, John, Moss, Rebecca A., Belyi, Vladimir, Chan, Chang S., Chen, Suzie, Goodell, Lauri, Foran, David, Yelensky, Roman, Palma, Norma A., Sun, James X., Miller, Vincent A., Stephens, Philip J., Ross, Jeffrey S., Kaufman, Howard, Poplin, Elizabeth, Mehnert, Janice, Tan, Antoinette R., Bertino, Joseph R., Aisner, Joseph, DiPaola, Robert S., Rodriguez-Rodriguez, Lorna, Ganesan, Shridar
Format: Online
Language:English
Published: AlphaMed Press 2016
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5189630/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5189630/

Similar Items